Selected article for: "acute respiratory distress syndrome and death lead"
Author: Ntatsoulis, Konstantinos; Karampitsakos, Theodoros; Tsitoura, Eliza; Stylianaki, Elli-Anna; Matralis, Alexios N.; Tzouvelekis, Argyrios; Antoniou, Katerina; Aidinis, Vassilis
Title: Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target
  • Cord-id: qerj93ny
  • Document date: 2021_10_4
    • ID: qerj93ny
    Snippet: Severe COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ failure and death. Interstitial lung diseases (ILD) and pulmonary fibrosis confer an increased risk for severe disease, while a subset of COVID-19-related ARDS surviving patients will develop a fibroproliferative response that can persist post hospitalization. Autotaxin (ATX) is a secreted lysophospholipase D, largely resp
    Document: Severe COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ failure and death. Interstitial lung diseases (ILD) and pulmonary fibrosis confer an increased risk for severe disease, while a subset of COVID-19-related ARDS surviving patients will develop a fibroproliferative response that can persist post hospitalization. Autotaxin (ATX) is a secreted lysophospholipase D, largely responsible for the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signaling lysophospholipid with multiple effects in pulmonary and immune cells. In this review, we discuss the similarities of COVID-19, ARDS and ILDs, and suggest ATX as a possible pathologic link and a potential common therapeutic target.

    Search related documents:
    Co phrase search for related documents
    • aclf chronic acute liver failure and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute exacerbation and adipose tissue: 1
    • acute exacerbation and liver disease: 1
    • acute exacerbation and liver failure: 1
    • acute lung injury and adipose tissue: 1, 2
    • acute lung injury and liver disease: 1, 2, 3, 4, 5, 6, 7
    • acute lung injury and liver failure: 1, 2, 3, 4, 5, 6, 7, 8
    • acute mouse lung injury and adipose tissue: 1
    • acute phase and adipose tissue: 1
    • acute phase and liver disease: 1, 2, 3, 4, 5, 6
    • acute phase and liver failure: 1, 2, 3, 4, 5
    • acute respiratory distress and additional therapeutic option: 1, 2, 3
    • acute respiratory distress and adipose tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory distress and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress and liver disease cancer: 1
    • acute respiratory distress and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and additional therapeutic option: 1, 2, 3
    • acute respiratory distress syndrome and liver disease cancer: 1
    • acute respiratory distress syndrome and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25